Combining two large clinical cohorts (AIBL and ADNI) to identify multiple lipid metabolic pathways in prevalent and incident Alzheimer’s disease
==================================================================================================================================================

* Kevin Huynh
* Wei Ling Florence Lim
* Corey Giles
* Kaushala S Jayawardana
* Agus Salim
* Natalie A Mellett
* Alex Smith
* Gavriel Olshansky
* Brian G Drew
* Pratishtha Chatterjee
* Ian Martins
* Simon M Laws
* Ashley I Bush
* Christopher C Rowe
* Victor L Villemagne
* David Ames
* Colin L Masters
* Matthias Arnold
* Kwangsik Nho
* Andrew J Saykin
* Rebecca Baillie
* Xianlin Han
* Rima Kaddurah-Daouk
* Ralph N Martins
* Peter J Meikle

## ABSTRACT

Changes to lipid metabolism are tightly associated with the onset and pathology of Alzheimer’s disease (AD). Lipids are complex molecules comprising of many isomeric and isobaric species, necessitating detailed analysis to enable interpretation of biological significance. Our expanded targeted lipidomics platform (569 lipid species across 32 lipid (sub)classes) allows for detailed isomeric and isobaric lipid separation. We applied the methodology to examine plasma samples from the Australian Imaging, Biomarkers and Lifestyle flagship study of aging (AIBL, n = 1112) and serum from the Alzheimer’s Disease Neuroimaging Initiative (ADNI, n = 800) studies. Cross sectional analysis using both cohorts identified concordant unique peripheral signatures associated with AD. Specific pathways include; sphingolipids, including GM3 gangliosides, where their acyl composition drove the major associations, and lipids previously associated with dysfunctional lipid metabolism in cardiometabolic disease including the phosphatidylethanolamine and triglyceride classes. Infomation derived from improved isomeric seperation highlighted pathway-specific changes with ether lipids including plasmalogens implicating perixosmal dysfunction in disease pathology. Longitudinal analysis revealed similar lipid signitures in both AIBL and ADNI cohorts with future disease onset. We utilised the two independent studies to train and validate multivariate lipid models that significantly improved disease classification and prediction. Together our results provide a holistic view of the lipidome and its relationship with AD using a comprehensive lipidomics approach, providing targets for further mechanistic investigation.

## INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disease characterised by progressive decline in cognitive function, usually presenting with memory loss. In the sporadic form of AD, symptoms usually begin to manifest after the age of 65, and with the ageing global population, the number of people with AD has been estimated to reach 81 million worldwide by 2040 1. The failure of many AD clinical trials over recent years has led to the call for a paradigm shift in AD research. It is now recognised that additional underlying mechanisms are involved in the pathogenesis of AD. We seek to provide a deeper molecular understanding of metabolic pathways implicated in AD to identify key enzymes, transporters and signalling molecules that are most amenable for therapeutic targeting. As there no appropriate sporadic mouse models of AD, human studies are essential for better understanding pathogenesis of AD. In particular, statistically powered studies are needed to detect the associations beneath the natural human biological variation.

Lipids are fundamental to every living system. These diverse and biologically important molecules comprise of thousands of individual species, spanning multiple classes and subclasses. In plasma, the majority of lipids are small amphiphilic molecules (including cholesterol) that make up the circulating lipoprotein particles such as high- & low- density lipoprotein (HDL & LDL). With recent advances to mass spectrometry and high-performance liquid chromatography, it is now feasible to examine in detail the comprehensive plasma lipidome in a human population or clinical study2. Quantification and characterisation of these diverse lipid molecules form the foundation of the field known as lipidomics.

Evidence that lipids are involved in AD have been demonstrated via alterations observed in phospholipid 3-5, plasmalogens6, ceramide 7, ganglioside 8, and sulfatide 7, 9 compositions in the brain. Several recent studies indicate that altered phospholipid metabolism associated with AD pathogenesis is also observed in the blood 5, 10, 11, thus encouraging discovery studies for blood-based lipid markers. Furthermore, a recent large-scale genome-wide association meta-analysis has identified genes involved in lipid metabolism as key risk factors for AD 12

The plasma lipidome is complex and consists of many isomeric and isobaric species 13, these are species that share similar or identical elemental composition but might be structurally different and offer distinct interprations. Existing lipidomic studies often employ techniques that provide poor resolution of these species 5, 14-17 limiting their biological interpretation. We have recently expanded our lipidomic platform to better characterise isomeric lipid species, now measuring 569 lipids from 32 classes and subclasses. Our methodology focuses on lipid and lipid-like compounds utilising extensive chromatographic separation. We have applied this method to two independent studies of ageing and Alzheimer’s disease; The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of ageing and the Alzheimer’s Disease Neuroimaging Initiative 1 (ADNI1) cohorts. Here we show the importance of capturing the comprehensive lipidome and highlight the necessity of obtaining molecular structural detail to identify key lipid pathways to link the plasma lipidome with AD and future onset of AD.

## METHODS

### Participants

The AIBL study recruited 1,112 individuals over the age of 60 years into a longitudinal study 18 At baseline, this comprised of 768 cognitively normal, 133 with mild cognitive impairment and 211 with AD. Time points for blood/data collection were every 18 months from baseline. Detailed description of the participants was adapted from Ellis *et al*. 18 We utilised all available fasted plasma samples (4,106) from baseline up to the 5th time point.

The ADNI1 study started in 2004 and recruited about 800 individuals at baseline. The initial goal was to recruit 200 particpants with mild AD and 200 controls as well as 400 particpants with MCI. Study data analysed here were obtained from the ADNI database, which is freely available online ([http://adni.loni.usc.edu/](http://adni.loni.usc.edu/)). We utilised serum samples from the ADNI1 baseline cohort.

### Classification of disease state

Classification of MCI and AD in the AIBL cohort has been described extensively in previous publications (*Ellis et al 2009* 18). Clinical criteria used to determine disease status included: Mini Mental State Examination score of less than 28, failure on the Logical Memory test (in accordance with the Alzheimer’s Disease Neuroimaging Initiative criteria), other evidence of possible significant cognitive difficulty on neuropsychological testing, a Clinical Dementia Rating score of 0.5 or greater, a medical history suggestive of the presence of illnesses likely to impair cognitive function, an informant or personal history suggestive of impaired cognitive function, or who were consuming medications or other substances that could affect cognition 18 A more in-depth description of the ADNI cohort diagnostic criteria is reported elsewhere 19, briefly, AD dementia diagnosis was established using NINDS-ADRDA criteria for probable AD. Classification as MCI followed the Petersen et al criteria previously described 20.

### Lipid extraction and liquid chromatography mass spectrometry

Lipids were extracted from 10 μL plasma (AIBL) or serum (ADNI), with the addition of an internal standard mix (Supplementary Table 1), using the single phase butanol/methanol extraction method as described previously 21. Analysis of plasma extracts was performed on an Agilent 6490 QQQ mass spectrometer with an Agilent 1290 series HPLC system. Mass spectrometry settings and transitions for each lipid class are shown in Supplementary Table 1. Additional experiments using pooled samples were utilised under varying conditions to get acyl composition data. Detailed description of the method and characterisation of lipid composition and identification of isobaric and isomeric species have been described previously 22 The additional experiments to characterise the lipid species include acid hydrolysis, fragmentation in the the presence of lithium ions in positive ionisation mode and fragmentation in negative ionisation mode 22.

View this table:
[Table 1](http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114215/T1)

Table 1 - Summary of modelling statistics

### Data integration, batch alignment and univariate statistical analysis

Peak area of the lipid species was related to the internal standards to generate concentration data. To remove technical batch variation, the lipid data in each analytical batch (approximately 486 samples a batch) was aligned by using the median value of each lipid of the plasma quality control samples. Final lipid concentrations were log10 transformed prior to statistical analysis.

For logistic and Cox regression, lipid data was scaled by the standard deviation and mean centered. Common covariates utilised in statistical analysis include age, sex, BMI, HDL cholesterol, total cholesterol, clinical triglycerides, statin use and omega-3 supplementation. Correction for multiple hypothesis testings was done using Benjamini and Hochberg’s false discovery rate (FDR). Meta-analysis to combine the results between the two cohorts was conducted using an inverse-variance weighted averaged fixed effect meta-analysis.

### Multivariate modelling of Alzheimer’s disease

We leveraged availability of two independent cohorts to train and test several lipid models for currently diagnosed and future incident AD. To define a feature list, in the training cohort we generated a series of models, using forward stepwise regression on top of covariates (to a maximum of 5 lipids per model), minimising Akaike Information Criterion (AIC) under a 10-fold cross validation framework. The frequency of incorporation, after accounting for clustering of co-linear lipids, was used to define features that were used to create a final model in the test set. For testing, the coefficients were generated on 9/10ths of the cohort and tested on the remaining. The concordance statistic (C-statistic) and net reclassification index (NRI) was calculated after 200 repeats. This process was repeated both ways, where AIBL and ADNI were utilised as training and test sets.

### Naming convention of lipid species

The lipid naming convention used here follows the guidelines established by the Lipid Maps Consortium and the shorthand notation established by Liebisch *et al* 23-25 We identified several species of interest that are not structurally resolved. These species separated chromatographically but incompletely characterised were labelled with an (a) or (b) to differentiate them, for example PC(P-17:0/20:4) (a) and PC(P-17:0/20:4) (b) where (a) and (b) represent the elution order. Separated isoforms that contain a 16:0 methyl branched fatty acids are presented as MHDA.

## RESULTS

### Lipidomic analysis of the AIBL and ADNI cohort

Between the two cohorts, a total of 5,733 samples (including quality controls and blanks) on 1912 unique individuals were analysed. The characteristics of individuals in the cross-sectional analysis are shown in Supplementary Table 2.

We developed our platform to better characterise the lipids in human plasma 22 In total we are able to examine 32 lipid classes and subclasses for both cohorts. In general, a similar correlation structure was observed within the AIBL and ADNI cohorts between lipid classes and many clinical measures (Figure 1). Many commonly reported lipid species associated with AD, such as sphingolipids and ether lipids, are often reported with ambiguous annotations, where the reported species are the sum of several isomers. Here we report the detailed characterisation of these species.

![Figure 1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/28/2020.05.26.20114215/F1.medium.gif)

[Figure 1](http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114215/F1)

Figure 1 Characterisation of lipid isomeric species and the relationship of lipid classes and subclasses within the AIBL and ADNI cohorts
**A** - Characterisation of sphingomyelin isomers. Black trace corresponds to the chromatogram seen under normal conditions. Additional experimental results in the green and blue traces used for identification, corresponding to SM(d18:1/24:1) and SM(d18:2/24:0) respectively. **B** - Characterisation of glycerophospholipid isomers. Black trace corresponds to the chromatogram seen under normal conditions. Red trace is the same scan after sample acid hydrolysis. **C** - Spearman correlation of total lipid classes, subclasses and commonly reported clinical measures for the AIBL baseline and ADNI studies.

Sphingolipids are structurally resolved through collision induced dissociation (CID), where fragments correspond to the sphingoid base, with the exception of sphingomyelins. Dissociation of sphingomyelin species under normal conditions results in a product ions that yields only sum composition data, i.e. the sphingomyelin species, SM(42:2). To determine sphingomyelin structural composition, we repeated the mass spectrometry analysis on pooled plasma samples in the presence of lithium acetate as described previously 22. The lithiated adduct of sphingomyelins produces product ions corresponding to the sphingoid base and n-acyl chain (Figure 1A) allowing for structural identification. Alignment through chromatography highlights that our measurement of SM(42:2) for example, is chromatographically separated into SM(d18:1/24:1) and SM(d18:2/24:0) (Figure 1A).

Similarly, this approach was repeated with the different glycerophospholipid classes to capture isomeric and isobaric structural detail where they were chromatographically resolved. Examination of the transition *m/z* 770.6 / 184.1 corresponding to the phosphatidylcholine / alkylphosphatidylcholine / alkenylphosphatidylcholine species PC(35:3) / PC(O-36:3) / PC(P-36:2) results in 9 distinct peaks (Figure 1B). Here were report complete separation of; diacyl odd-numbered phosphatidylcholine species, the non-plasmalogen ether lipids PC(O) and the plasmalogen ether lipids, PC(P). Results were confirmed by exploiting the susceptibility of plasmalogens to acid hydrolysis (Figure 1B).

### Concordance of associations between two studies with Alzheimer’s disease

After adjustment for covariates (including age, sex, BMI, total cholesterol, HDL-C, triglycerides, site of sample collection, APOE ε4 alleles, omega-3 supplementation, and statin use). There were 12 and 3 classes significantly associated with AD in the AIBL and ADNI1 cohorts respectively after FDR correction, corresponding to 184 and 97 lipids respectively (246 and 197 uncorrected, Figure 3). Meta-analysis using a fixed-effects model identified 218 lipids and 11 classes associated with AD between both cohorts (Figure 2 and 3). The lipid classes associated were predominately from the sphingolipid classes; dihydroceramides (dhCer), trihexosylceramides (Hex3Cer), GM3 gangliosides (GM3), GM1 gangliosides (GM1), and ether lipids classes; alkylphosphatidylcholine [PC(O)], alkenylphosphatidylcholine [PC(P)], alkylphosphatidylethanolamine [PE(O)], alkenylphosphatidylethanolamine [PE(P)], alkyldiacylglycerol [TG(O)].

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/28/2020.05.26.20114215/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114215/F2)

Figure 2. Associations of lipid class totals with prevalent and incident Alzheimer’s disease
Forest plots of lipid class associations for (A) prevalent Alzheimer’s disease and (B) Incident Alzheimer’s disease. Lipid classes are generated by the sum of each individual species measured in each class. Regressions are adjusted (at minimum) for age, sex, BMI, total cholesterol, HDL-C, triglycerides, number of APOE4 alleles, statin use and omega-3 supplementation. Grey squares, not significant, light squares, uncorrected p < 0.01, bolded squares, FDR corrected p < 0.05.

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/28/2020.05.26.20114215/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114215/F3)

Figure 3. Associations of individual lipid species with prevalent Alzheimer’s disease
Forest plot outlining the logistic regression results of individual species, between controls and prevalent AD in both the AIBL (blue n = 268 cases, 696 controls) and ADNI (red, n = 178 cases, 210 controls) cohorts with the combined meta-analysis in the middle (green). P-value was corrected for multiple comparison using approach by Benjamini and Hochberg. Covariates include age, sex, BMI, total cholesterol, HDLC, triglycerides, number of APOE4 alleles, statin use and omega-3 supplementation. Additional covariates for AIBL include site of blood collection and time point while ADNI includes fasting status. Open circles, not significant, closed dark circles, significant after FDR correction, coloured circles, top 20 associations ranked by p-value.

While all plasmalogens (alkenyl classes) are ether lipids, not all ether lipids are plasmalogens. This distinction is important when factoring in their biological significance. Independent of multiple covariates, the majority of the ether lipid classes were negatively associated with AD (Figure 2 and 3A). This effect is compounded when the ether lipids are esterified with omega-3 fatty acids, such as the 22:6 acyl chain (docosahexaenoic acid, DHA). However, it should be noted that ether lipids with polyunsaturated fatty acids other than omega-3 were still negatively associated with AD (Figure 3B, Supplementary Table 3), highlighting that the effect is not necessarily driven by omega-3 fatty acids. A non-glycerophospholipid subclass of ether lipids, alkyldiacylglycerols, TG(O), were negatively associated with AD, despite the species measured predominately containing saturated or monounsaturated species (Figures 2 and 3).

Ceramide and sphingomyelin species presented with both positive and negative associations with AD resulting in no significant associations at the class level. In both cohorts, dhCer was notability negatively associated with AD. Negative associations were primarily driven by 22:0 and 24:0 saturated species in the sphingolipid n-acyl moiety, while positive associations were predominately the shorter 18:0, 20:0 and monounsaturated 24:1 species. The sphingoid base had no apparent influence on the association in AD. This sphingolipid pattern in AD is much weaker in the ADNI1 cohort (Figure 3, Supplementary table 3).

This effect was also seen for other complex sphingolipids, where a positive association or trend was observed at the class level (monohexosylceramide, HexCer, dihexosyolceramide, Hex2Cer, Hex3Cer, GM3 and GM1 gangliosides) in both AIBL and ADNI cohorts (Figure 2), but individual species within these classes present with the same opposing relationship (negative association with the n-acyl chains 22:0, 24:0, positive association with the 18:0, 20:0 and 24:1 species). This combined trend resulted in no association with 22:0 and 24:0 n-acyl sphingolipids but an increased association in sphingolipids with n-acyl chains 18:0, 20:0 and 24:1, such as GM3(d18:1/24:1) which has the strongest positive association with AD (Figure 3, Supplementary table 3).

A notable pattern observed in both AIBL and ADNI cohorts, even after adjustment for clinical measures of cholesterol and triglycerides, was the positive associations of the lipid classes phosphatidylethanolamine, PE, and triglyceride, TG (Figure 3). This effect has been noted in diseases where dyslipidemia is prevalent such as T2D 26.

### Similar lipids are associated with cross sectional and longitudinal analysis of Alzheimer’s disease in both cohorts

We explored using cox regression models lipids associated with the risk of developing AD in the future. Baseline characteristics of this analysis are presented in Supplementary Table 2. After adjustment for covariates (age as time scale, sex, BMI, total cholesterol, HDL-C, triglycerides, site of sample collection, APOE ε4 alleles, omega-3 supplementation and statin use), there were 72 species associated with incident AD in the meta-analysis (Figure 4, Supplementary Table 4). 161 lipids had uncorrected p-values < 0.05 and the majority of these show the same direction of association as observed for AD (Figure 4A). These include individual species from the ether lipids, sphingolipids, phosphatidylethanolamine, and triglyceride classes.

![Figure 4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/28/2020.05.26.20114215/F4.medium.gif)

[Figure 4.](http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114215/F4)

Figure 4. Associations of individual lipid species with future onset Alzheimer’s disease
Forest plot outlining the logistic regression results of individual species, between non-converters and future converters in both the AIBL (light blue n = 68 cases, 714 controls) and ADNI (red, n = 166 cases, 397 controls) cohorts with the combined meta-analysis in the middle (green). P-value was corrected for multiple comparison using approach by Benjamini and Hochberg. Covariates include age (set as timescale), sex, BMI, total cholesterol, HDL-C, triglycerides, number of APOE4 alleles, statin use and omega-3 supplementation. Open circles, not significant, closed dark circles, uncorrected p-value, coloured squares, top 10/20 associations ranked by p-value.

### Multivariate modelling to identify lipids important in diagnosing prevalent or predicting future onset of Alzheimer’s disease

Due to the feature selection process (selecting features based on frequency incorporating into a multivariate model), we observed that informatively prognostic lipids, but are otherwise highly correlated, would frequently be selected once in each model interchangeably, reducing their individual frequency count. We utilised the correlation data to identify lipid clusters of highly correlated species. The frequency of these clusters were then used to rank (sum of individual incorporations), with the most incorporated lipid in each cluster used as the representative for the multivariate models (Supplementary Table 5).

#### Model development in the AIBL, tested in ADNI

In the disease classification model, we observed a final C-statistic of 0.752 (0.747 – 0.757) through the incorporation of 10 lipid species on top of the base model of age, sex, BMI and *APOE* ε4 count (C-statistic of 0.731 [0.726 – 0.736]) with a NRI of 0.40 when tested on the ADNI study. For incident AD, we observed a final C-statistic of 0.675 (0.671 – 0.680), up from 0.644 (0.640 – 0.648) obtained from the base model alone (NRI of 0.40). The summary of results is presented in Table 1.

#### Model development in the ADNI, tested in AIBL

In the parallel analysis, the disease classification model had a final C-statistic of 0.869 (0.866-0.871) through the incorporation of 10 lipid species on top of the base model of age, sex, BMI and *APOE* ε4 count (C-statistic of 0.820 [0.817-0.823]) with a NRI of 0.84 when tested on the AIBL study. For prediction of future disease onset, we observed a final C-statistic of 0.733 (0.727 – 0.740), up from 0.716 (0.709 – 0.723) obtained from the base model alone (NRI of 0.45). The summary of results is presented in Table 1.

## DISCUSSION

Here we present our initial results from the lipidomic analysis of the AIBL and ADNI cohorts. Our goal was to define the complex associations between lipids and AD using our updated methodology by examining each cohort independently and subsequently combining them in a single meta-analysis.The independent nature of these two studies allows for confidence in identifying lipids that are important in AD pathology.

### Multiple lipid classes are positively associated with Alzheimer’s disease

The positive associations of phosphatidylethanolamine, diacylglycerol, and triacylglycerol with AD is similar to the associations seen with both pre-diabetes and type 2 diabetes 26. These species tend to correlate closely with clinically elevated levels of triglycerides and reduced HDL cholesterol (dyslipidemia); adjustment for these clinical lipid measures resulted in a loss of significance at the class level; however multiple species within these classes retained a significant association with AD (Figure 3). Interestingly, we observe mostly monounsaturated acyl species driving the associations within these classes. Several studies have highlighted the association of dyslipidemia and insulin resistance with the risk of both vascular dementia and AD 27, 28. It may also be possible that the positive association observed with the PE class is a compensatory increase due to the decreases of PE(P) species, a phenomenon that has been reported in plasmalogen-deficient mice 29.

### Both alkyl and alkenyl ether lipids are negatively associated with Alzheimer’s disease

A key difference between plasmalogens and non-plasmalogen ether lipids is the vinylether bond in the *sn1* position, which is susceptible to oxidation 30. Little of the recently reported metabolomic literature with respect to AD has differentiated these two classes 5,14-17. To further complicate this issue, studies which have obtained data from unit resolution mass spectrometers were unable to differentiate these species from isobaric species (odd numbered di-acyl lipids), unless extensive chromatography has also been employed. For example, PC(35:2) has a mass difference of 0.036 Da from PC(O-36:2) and PC(P-36:1), of which the latter two share identical masses (isomeric). When measured on a unit-resolution instrument without chromatography 5, these all contribute to the same signal. This can raise issues in instances where these species associate differently with the outcome. This is exemplified in the inverse relationship of odd-chain and ether lipids with AD (Supplementary Table 3), highlighting the importance of differentiating these species.

It has been proposed that plasmalogens act as endogenous antioxidants through their vinyl-ether bond and that increased oxidative stress may explain the lower levels observed in AD patients 31. However, both plasmalogen and non-plasmalogen ether species showed similar associations with AD. Alkyl ether lipids are less susceptible to oxidation compared to their plasmenyl counterparts, suggesting associations with AD more likely reflect changes to the biosynthetic pathway. In support of this, Grimm et al. reported dysregulation of the peroxisomal enzymes relating to plasmalogen synthesis in AD 32. Plasmalogens have been reported to be involved in several physiological functions including maintenance of lipid raft domains 33 which are important for secretase function, responsible for Aβ production 34, cholesterol efflux 35 and cellular survival 36. Importantly, peripheral intravenous administration of plasmalogens has been shown to inhibit Aβ accumulation in a study involving neuroinflammation 37. Impairment to the synthetic pathway of ether lipids may have deleterious downstream effects, and, in fact, these species have been proposed as potential therapeutic compounds 38.

### Sphingolipids highlight complex acyl associations with Alzheimer’s disease

We have observed diverse associations of specific n-acylated ceramides with AD: positive associations were observed with species containing 18:0, 20:0 and 24:1 fatty acids; whereas negative or neutral associations were observed for species containing 22:0, 24:0 and 26:0 fatty acids, irrespective of the sphingoid base. In contrast, significant associations of sphingolipids with incident AD were only observed for species containing nervonic acid (24:1). This effect was much stronger in the AIBL study, while ADNI exhibited similar trends but were not significant after FDR correction. Despite this, the meta analysis of sphingolipid associations resulted in much more power than utilising the AIBL study alone (Supplementary table 3).

Synthesis of 24:1 is likely through elongation of 18:1 which itself is synthesized through unsaturation via stearoyl-CoA desaturase 1 (SCD-1). Interestingly, increased SCD-1 activity has previously been associated with AD 39, and this may be contributing to the increased abundance of these monounsaturated lipid species. We observed similar positive associations with 18:1 relative to 18:0 in many of our measured lipid species, particularly species with a single fatty acid (e.g. LPC and CE species, Supplementary Table 3). Interestingly SCD-1 is associated with insulin resistance and adiposity, and mouse experiments have shown that disrupting SCD-1 function can potentially reduce body adiposity and improve insulin sensitivity 40. This is relevant as obesity, insulin resistance and diabetes type II are all likely linked to increased risk of AD 41

Specific ceramide synthases are responsible for the n-acylation of ceramide species, in particular, ceramide synthase 2 (20:0 to 26:0) and 3 (22:0 to 26:0) 42. Decreases in the activity of ceramide synthase 2 (CerS2) have been observed in AD, early in pathogenesis 43. Thus the negative association of Cer(22:0), Cer(24:0) and Cer(26:0) may be driven by decreases of CerS2; while the positive association of Cer(24:1) driven by SCD-1, cancels out the negative association observed with CerS2 which would, on its own, be expected to result in decreased levels of this species.

Gangliosides are a group of sphingolipids with oligosaccharide groups linked to the sphingoid base. GM3 gangliosides, the most abundant circulating ganglioside class, is positively associated with AD. Gangliosides have been reported to accelerate Aβ aggregation, leading to deposition in the brain 44. While the mechanism leading to increased circulating gangliosides is currently not known, gangliosides are not commonly measured, and thus far no other reports have described an association between circulating GM3 gangliosides and AD.

### Multivariate modelling of lipids in Alzheimer’s disease

We were able to identify several lipids that appear to be key in identifying individuals that have, or are at risk of developing AD. These lipids highlight unique features that provide information on top of easily obtained anthropometric (age, sex, BMI) and biochemical features (*APOE* ε4 alleles). While we were able to test and validate these models across the two cohorts, ultimately a population study will be required to fully assess model performance.

### Concluding remarks

We have performed one of the most comprehensive lipidomic analysis of AD to date by utilising two large, independent clinical studies in AD. We have provided a holistic picture of lipid dysregulation associated with both prevalent and incident AD. Our plasma lipid dataset expands the scientific literature by providing greater resolution and allowing fine-granular analysis of the lipidome. Here we have highlighted specific changes to the ether lipid pathway, where plasmalogens are not the only drivers of ether lipid associations. Class-wide and species-specific changes highlight the necessity of a broad and detailed assay to capture these minute differences in the lipidome. We have demonstrated the potential of plasma lipids as the markers to improve assessment of prevalent and incident AD, highlighting the importance of these small molecules in both disease prognostics and understanding the metabolic changes occurring with the disease.

## Data Availability

Data to support this finding is available online and upon request. The entire ADNI lipidomic and clinical characteristic data is available online (adni.loni.usc.edu) and the remaining data (ABIL) used in this study is available from both the corresponding authors and online at https://aibl.csiro.au upon reasonable request.

## CONFLICTS OF INTEREST

A provisional patent has been filed using the AIBL data. Application number: App Number 2018901220; DEMENTIA RISK ANALYSIS; Baker Heart and Diabetes Institute, Edith Cowan University

:   ABBREVIATONS
Cer
:   ceramide;
CE
:   cholesteryl ester;
COH
:   free cholesterol;
DE
:   dehydrocholesterol ester;
DG
:   diacylglycerol;
dhCer
:   dihydroceramide;
GM1
:   GM1 ganglioside;
GM3
:   GM3 ganglioside;
HexCer
:   monohexosylceramide;
Hex2Cer
:   dihexosylceramide;
Hex3Cer
:   trihexosylceramide;
LPC
:   lysophosphatidylcholine;
LPC(O)
:   lysoalkylphosphatidylcholine;
LPC(P)
:   lysoalkenylphosphatidylcholine;
LPE
:   lysophosphatidylethanolamine;
LPE(P)
:   lysoalkenylphosphatidylethanolamine;
LPI
:   lysophosphatidylinositol;
PC
:   phosphatidylcholine;
PC(O)
:   alkylphosphatidylcholine;
PC(P)
:   alkenylphosphatidylcholine (PC plasmalogen);
PE
:   phosphatidylethanolamine;
PE(O)
:   alkylphosphatidylethanolamine;
PE(P)
:   alkenylphosphatidylethanolamine (PE plasmalogen);
:   PG phosphatidylglycerol;
PI
:   phosphatidylinositol;
PS
:   phosphatidylserine;
SM
:   sphingomyelin;
TG
:   triglyceride;
TG(O)
:   alkyldiacylglycerol.

## ACKNOWLEDGEMENTS

Funding for the AIBL study was provided in part by the study partners [Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), National Ageing Research Institute (NARI), Austin Health, CogState Ltd.]. The AIBL study has also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as funding from the Science and Industry Endowment Fund (SIEF) and the Cooperative Research Centre (CRC) for Mental Health – funded through the CRC Program (Grant ID:20100104), an Australian Government Initiative. The authors thank the AIBL study participants for their contribution to the study. K.H was supported by a Dementia Australia Research Foundation Scholarship. PJM is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. Support for the metabolomics sample processing, assays and analytics reported here was provided by grants from the National Institute on Aging (NIA); NIA supported the Alzheimer’s Disease Metabolomics Consortium which is a part of NIA’s national initiatives AMP-AD and M2OVE-AD (R01 AG046171, RF1 AG051550, RF1 AG057452, and 3U01 AG024904-09S4). Additional NIH support from the NIA, NLM and NCI for analysis includes P30 AG10133, R01 AG19771, R01 LM012535, R03 AG054936, R01 AG061788, K01 AG049050 and R01 CA129769. M.A. is supported by National Institute on Aging grants RF1 AG057452, RF1 AG058942, RF1 AG059093, and U01 AG061359. M.A. is also supported by funding from Qatar National Research Fund NPRP8-061-3-011. K.N is supported by NLM R01 LM012535 and NIA R03AG054936.This work was also supported in part by the Victorian Government’s Operational Infrastructure Support Program.

Data collection and sharing for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was supported by National Institutes of Health Grant U01 AG024904. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

This study was only possible with the help of the AIBL research group. Authors that made direct contribution to this study has been listed as authors in this article. Members of the AIBL group that did not participate in the analysis or writing of this report are listed here; [https://aibl.csiro.au/about/aibl-research-team/](https://aibl.csiro.au/about/aibl-research-team/)

Part of the data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). Authors that made direct contribution to this study has been listed as authors in this article. As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\_to\_apply/ADNI\_Acknowledgement\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how\_to_apply/ADNI_Acknowledgement_List.pdf)

Part of the data used in preparation of this article were generated by the Alzheimer’s Disease Metabolomics Consortium (ADMC). Authors that made direct contribution to this study has been listed as authors in this article. Investigators within the ADMC provided data but did not participate in analysis or writing of this report can be found at: [https://sites.duke.edu/adnimetab/team/](https://sites.duke.edu/adnimetab/team/)

## Footnotes

*   * Joint first authors

*   ^ joint senior and corresponding authors.

*   Received May 26, 2020.
*   Revision received May 26, 2020.
*   Accepted May 28, 2020.


*   © 2020, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## REFERENCES

1.  1.Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112–2117.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(05)67889-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16360788&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000234146000026&link_type=ISI) 

2.  2.Burla B, Arita M, Arita M, Bendt AK, Cazenave-Gassiot A, Dennis EA et al. MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines. 2018; 59(10): 2001–2017.
    
    

3.  3.Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. Journal of lipid research 2007; 48(11): 2485–2498.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamxyIjtzOjU6InJlc2lkIjtzOjEwOiI0OC8xMS8yNDg1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDUvMjgvMjAyMC4wNS4yNi4yMDExNDIxNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

4.  4.Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer’s disease prefrontal cortex. Journal of Alzheimer’s disease: JAD 2011; 24(3): 507–517.
    
    

5.  5.Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014; 20(4): 415–418.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.3466&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24608097&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

6.  6.Han XL, Holtzman DM, McKeel DW. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. Journal of Neurochemistry 2001; 77(4): 1168–1180.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1046/j.1471-4159.2001.00332.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11359882&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000168771600022&link_type=ISI) 

7.  7.Cheng H, Zhou Y, Holtzman DM, Han X. Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer’s disease. Neurobiol Aging 2010; 31(7): 1188–1196.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neurobiolaging.2008.07.020&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18762354&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000278438300011&link_type=ISI) 

8.  8.Yamamoto N, Igbabvoa U, Shimada Y, Ohno-Iwashita Y, Kobayashi M, Wood WG et al. Accelerated Abeta aggregation in the presence of GM1-ganglioside- accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS letters 2004; 569(1-3): 135–139.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.febslet.2004.05.037&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15225622&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000222548500024&link_type=ISI) 

9.  9.Han X,  M. Holtzman D,  W. McKeel D, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. Journal of Neurochemistry 2002; 82(4): 809–818.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1046/j.1471-4159.2002.00997.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12358786&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000177369300009&link_type=ISI) 

10. 10.Chatterjee P, Lim WL, Shui G, Gupta VB, James I, Fagan AM et al. Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study. Journal of Alzheimer’s disease: JAD 2016.
    
    

11. 11.Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer’s disease. Neurobiology of aging 2014; 35(2): 271–278.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neurobiolaging.2013.08.001&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24041970&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

12. 12.Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature genetics 2019; 51(3): 404–413.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

13. 13.Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010; 51 (11): 3299–3305.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamxyIjtzOjU6InJlc2lkIjtzOjEwOiI1MS8xMS8zMjk5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDUvMjgvMjAyMC4wNS4yNi4yMDExNDIxNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

14. 14.Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, Chidambaram S, Tan MT et al. Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease. Frontiers in neurology 2015; 6: 237.
    
    

15. 15.Li D, Misialek JR, Boerwinkle E, Gottesman RF, Sharrett AR, Mosley TH et al. Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2016; 3: 73–82.
    
    

16. 16.Koal T, Klavins K, Seppi D, Kemmler G, Humpel C. Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. Journal of Alzheimer’s disease: JAD 2015; 44(4): 1193–1201.
    
    

17. 17.Casanova R, Varma S, Simpson B, Kim M, An Y, Saldana S et al. Blood metabolite markers of preclinical Alzheimer’s disease in two longitudinally followed cohorts of older individuals. Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2016; 12(7): 815–822.
    
    

18. 18.Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. International Psychogeriatrics 2009; 21(4): 672–687.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S1041610209009405&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19470201&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000268507700008&link_type=ISI) 

19. 19.Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J et al. Impact of the Alzheimer’s Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2015; 11 (7): 865–884.
    
    

20. 20.Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74(3): 201–209.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/WNL.0b013e3181cb3e25&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20042704&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

21. 21.Alshehry ZH, Barlow CK, Weir JM, Zhou Y, McConville MJ, Meikle PJ. An Efficient Single Phase Method for the Extraction of Plasma Lipids. Metabolites 2015; 5(2): 389–403.
    
    

22. 22.Huynh K, Barlow CK, Jayawardana KS, Weir JM, Mellett NA, Cinel M et al. High-Throughput Plasma Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors. Cell chemical biology 2018.
    
    

23. 23.Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH, Jr.., Murphy RC et al. A comprehensive classification system for lipids. J Lipid Res 2005; 46(5): 839–861.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamxyIjtzOjU6InJlc2lkIjtzOjg6IjQ2LzUvODM5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDUvMjgvMjAyMC4wNS4yNi4yMDExNDIxNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

24. 24.Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T et al. Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res 2009; 50 Suppl: S9–14.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamxyIjtzOjU6InJlc2lkIjtzOjE2OiI1MC9TdXBwbGVtZW50L1M5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDUvMjgvMjAyMC4wNS4yNi4yMDExNDIxNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

25. 25.Liebisch G, Vizcaino JA, Kofeler H, Trotzmuller M, Griffiths WJ, Schmitz G et al. Shorthand notation for lipid structures derived from mass spectrometry. J Lipid Res 2013; 54(6): 1523–1530.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamxyIjtzOjU6InJlc2lkIjtzOjk6IjU0LzYvMTUyMyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzA1LzI4LzIwMjAuMDUuMjYuMjAxMTQyMTUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

26. 26.Meikle PJ, Wong G, Barlow CK, Weir JM, Greeve MA, MacIntosh GL et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One 2013; 8(9): e74341.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0074341&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24086336&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

27. 27.Raffaitin C, Gin H, Empana J-P, Helmer C, Berr C, Tzourio C et al. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City Study. Diabetes care 2009; 32(1): 169–174.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiZGlhY2FyZSI7czo1OiJyZXNpZCI7czo4OiIzMi8xLzE2OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzA1LzI4LzIwMjAuMDUuMjYuMjAxMTQyMTUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

28. 28.Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. Journal of diabetes investigation 2013; 4(6): 640–650.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/jdi.12087&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24843720&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000327442200019&link_type=ISI) 

29. 29.Dorninger F, Brodde A, Braverman NE, Moser AB, Just WW, Forss-Petter S et al. Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens. Biochimica et biophysica acta 2015; 1851(2): 117–128. 612
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.bbalip.2014.11.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25463479&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

30. 30.Nagan N, Zoeller RA. Plasmalogens: biosynthesis and functions. Prog Lipid Res 2001; 40(3): 199–229.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0163-7827(01)00003-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11275267&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000167751300003&link_type=ISI) 

31. 31.Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PWK et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. Journal of Lipid Research 2007; 48(11): 2485–2498.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamxyIjtzOjU6InJlc2lkIjtzOjEwOiI0OC8xMS8yNDg1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDUvMjgvMjAyMC4wNS4yNi4yMDExNDIxNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

32. 32.Grimm MOW, Kuchenbecker J, Rothhaar TL, Groesgen S, Hundsdoerfer B, Burg VK et al. Plasmalogen synthesis is regulated via alkyl- dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer’s disease. Journal of Neurochemistry 2011; 116(5): 916–925.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1471-4159.2010.07070.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21214572&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000287145600035&link_type=ISI) 

33. 33.Pike LJ, Han XL, Chung KN, Gross RW. Lipid rafts are enriched in plasmalogens and arachidonate-containing phospholipids and the expression of caveolin does not alter the lipid composition of these domains. Faseb J 2001; 15(4): A20–A20.
    
    

34. 34.Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer’s disease betaamyloid production. Biochimica et biophysica acta 2010; 1801(8): 860–867.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.bbalip.2010.03.007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20303415&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000279476000016&link_type=ISI) 

35. 35.Mandel H, Sharf R, Berant M, Wanders RJA, Vreken P, Aviram M. Plasmalogen Phospholipids Are Involved in HDL-Mediated Cholesterol Efflux: Insights from Investigations with Plasmalogen-Deficient Cells. Biochem Biophys Res Commun 1998; 250(2): 369–373.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1006/bbrc.1998.9321&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9753636&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000076088000032&link_type=ISI) 

36. 36.Zoeller RA, Grazia TJ, LaCamera P, Park J, Gaposchkin DP, Farber HW. Increasing plasmalogen levels protects human endothelial cells during hypoxia. American journal of physiology Heart and circulatory physiology 2002; 283(2): H671–679.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1152/ajpheart.00524.2001&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12124215&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000176880500027&link_type=ISI) 

37. 37.Ifuku M, Katafuchi T, Mawatari S, Noda M, Miake K, Sugiyama M et al. Anti- inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. Journal of neuroinflammation 2012; 9: 197.
    
    

38. 38.Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S et al. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. EBioMedicine 2017; 17: 199–205.
    
    

39. 39.Astarita G, Jung K-M, Vasilevko V, DiPatrizio NV, Martin SK, Cribbs DH et al. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease. PLoS One 2011; 6(10): e24777.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0024777&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22046234&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

40. 40.Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS et al. Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity. Proceedings of the National Academy of Sciences 2002; 99(17): 11482–11486.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiOTkvMTcvMTE0ODIiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMC8wNS8yOC8yMDIwLjA1LjI2LjIwMTE0MjE1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

41. 41.Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux RJAjoe. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. 2001; 154(7): 635–641.
    
    

42. 42.Levy M, Futerman Anthony H. Mammalian ceramide synthases. IUBMB life 2010; 62(5): 347–356.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/iub.319&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20222015&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000277602000004&link_type=ISI) 

43. 43.Couttas TA, Kain N, Suchowerska AK, Quek LE, Turner N, Fath T et al. Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer’s disease. Neurobiol Aging 2016; 43: 89–100.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neurobiolaging.2016.03.027&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27255818&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F28%2F2020.05.26.20114215.atom) 

44. 44.Hoshino T, Mahmood MI, Mori K, Matsuzaki K. Binding and aggregation mechanism of amyloid beta-peptides onto the GM1 ganglioside-containing lipid membrane. The journal of physical chemistry B 2013; 117(27): 8085–8094.